Successful lamivudine therapy for post-chemotherapeutic fulminant hepatitis B in a hepatitis B virus carrier with non-Hodgkin's lymphoma: Case report and review of the literature

被引：0
作者：
Kawai Y. [1 ]
Ikegaya S. [2 ]
Hata M. [1 ]
Kawahito M. [1 ]
Imamura S. [1 ]
Yoshida A. [1 ]
Tsutani H. [1 ]
Ueda T. [1 ]
机构：
[1] First Department of Internal Medicine, Fukui Medical University, Fukui 910-1193
[2] Second Department of Pathology, Fukui Medical University, Fukui 910-1193
来源：
Annals of Hematology | 2001年 / 80卷 / 8期
关键词：
Chemotherapy; Fulminant hepatitis B; Lamivudine; Malignant lymphoma;
D O I：
10.1007/s002770100322
中图分类号：
学科分类号：
摘要：
Reactivation of hepatitis B virus (HBV), especially after withdrawal of corticosteroids is a well-known complication during chemotherapy for lymphoma. The high mortality makes this complication one of the major obstacles to completing the standard treatment for lymphoma in HBV carriers. We report a 58-year-old Japanese male HBV carrier who developed fulminant hepatitis after chemotherapy with cyclophosphamide and doxorubicin. Lamivudine was introduced since his hepatitis was progressive under supportive treatment and showed an elevated level of HBV DNA. After initiation of lamivudine, HBV DNA decreased to be below the limit of detection within 3 weeks, and all chemical tests for liver function recovered to the normal level within 4 weeks, except for a slight elevation of total-bilirubin. There were no remarkable adverse effects observed. To the best of our knowledge, six cases of post-chemotherapeutic fulminant hepatitis including ours have been treated with lamivudine. A review of these cases indicated that lamivudine induced a prompt antiviral, biochemical, and clinical response. Lamivudine is highly recommended for post-chemotherapeutic fulminant hepatitis caused by reactivation of HBV.
引用
收藏
页码：482 / 484
页数：2
相关论文
共 17 条
  • [1] Ahmed A., Keeffe E.B., Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection, Am J Gastroenterol, 94, pp. 249-251, (1999)
  • [2] Al-Taie O.H., Mork H., Gassel A.M., Wilhelm M., Weissbrich B., Scheurlen M., Prevention of hepatitis B flare-up during chemotherapy using lamivudine: Case report and review of the literature, Ann Hematol, 78, pp. 247-249, (1999)
  • [3] Clark F.L., Drummond M.W., Chambers S., Chapman B.A., Patton W.N., Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma, Ann Oncol, 9, pp. 385-387, (1998)
  • [4] Honkoop P., Niesters H.G., de Man R.A., Osterhaus A.D., Schalm S.W., Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns, J Hepatol, 26, pp. 1393-1395, (1997)
  • [5] Hoofnagle J.H., Dusheiko G.M., Schafer D.F., Jones E.A., Micetich K.C., Young R.C., Costa J., Reactivation of chronic hepatitis B virus infection by cancer chemotherapy, Ann Intern Med, 96, pp. 447-449, (1982)
  • [6] Iwasaki H., Ueda T., Inai K., Tsutani H., Uchida M., Nakamura T., Fulminant hepatitis cured by plasma exchange in a patient with acute leukemia-a case report (in Japanese), Rinsho Ketsueki, 32, pp. 272-276, (1991)
  • [7] Kumagai K., Takagi T., Nakamura S., Sawada U., Kura Y., Kodama F., Shimano S., Kudoh I., Nakamura H., Sawada K., Ohnoshi T., Hepatitis B virus carriers in the treatment of malignant lymphoma: An epidemiological study in Japan, Ann Oncol, 8, pp. 107-109, (1997)
  • [8] Lai C.L., Chien R.N., Leung N.W., Chang T.T., Guan R., Tai D.I., Ng K.Y., Wu P.C., Dent J.C., Barber J., Stephenson S.L., Gray D.F., A one-year trial of lamivudine for chronic hepatitis B, N Engl J Med, 339, pp. 61-68, (1998)
  • [9] Ling R., Mutimer D., Ahmed M., Boxall E.H., Elias E., Dusheiko G.M., Harrison T.J., Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine, Hepatology, 24, pp. 711-713, (1996)
  • [10] Maguire C.M., Crawford D.H., Hourigan L.F., Clouston A.D., Walpole E.T., Powell E.E., Case report: Lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy, J Gastroenterol Hepatol, 14, pp. 801-803, (1999)
12